D-erythro-Eritadenine, also known as Erythadenine, is a compound with potential cholesterol-lowering properties that has garnered attention in the field of nutrition and health. Studies suggest that Erythadenine may help to reduce cholesterol levels by inhibiting the enzyme involved in cholesterol synthesis. As high cholesterol is a risk factor for cardiovascular diseases, including heart attacks and strokes, compounds like Erythadenine hold promise for improving heart health and overall well-being. Incorporating Erythadenine-rich foods into one’s diet or considering supplementation may therefore have a positive impact on individual health outcomes and reduce the risk of cardiovascular complications.
Table of Contents:
- 💡 Commercial Applications
- ⚗️ Chemical & Physical Properties
- 🏭 Production & Procurement
- ⚠️ Safety Considerations
- 🔬 Potential Research Directions
- 🧪 Related Compounds
💡 Commercial Applications
D-erythro-Eritadenine, a bioactive compound found in shiitake mushrooms, has various commercial and industrial applications. It is commonly used as a food additive in the form of a dietary supplement due to its cholesterol-lowering properties. Additionally, D-erythro-Eritadenine is utilized in the production of functional foods and beverages meant to promote heart health and overall well-being.
In terms of drug and medication applications, D-erythro-Eritadenine has shown potential as a therapeutic agent for cardiovascular diseases. Studies have demonstrated its ability to lower serum cholesterol levels by inhibiting cholesterol absorption in the intestines. As a result, pharmaceutical companies are exploring the inclusion of D-erythro-Eritadenine in cholesterol-lowering medications to improve their efficacy in managing heart health.
⚗️ Chemical & Physical Properties
D-erythro-Eritadenine is a white, odorless solid substance with a crystalline appearance. It is typically found in powder form.
The molar mass of D-erythro-Eritadenine is approximately 215.22 g/mol, and it has a density of about 1.47 g/cm³. Compared to common food items, D-erythro-Eritadenine has a higher molar mass but lower density than sugar and salt.
D-erythro-Eritadenine has a melting point of around 215-217°C and a boiling point of approximately 370-372°C. Compared to common food items like butter and chocolate, D-erythro-Eritadenine has a higher melting point and boiling point.
D-erythro-Eritadenine is sparingly soluble in water and has a low viscosity. In comparison to sugar and salt, D-erythro-Eritadenine has lower solubility in water and viscosity.
🏭 Production & Procurement
D-erythro-Eritadenine is primarily produced through the fermentation of Aspergillus spores on a substrate containing adenosine. This process allows for the conversion of adenosine to D-erythro-Eritadenine, a biologically active compound that has been studied for its potential health benefits.
The procurement of D-erythro-Eritadenine typically involves sourcing the compound from specialized suppliers who have the capability to produce it in large quantities through fermentation processes. Once produced, D-erythro-Eritadenine can be transported in various forms, including powdered or liquid formulations, depending on the intended application.
In the transportation of D-erythro-Eritadenine, care must be taken to ensure the stability and purity of the compound during transit. This may involve packaging the compound in sealed containers, protecting it from exposure to light and moisture, and maintaining appropriate temperature conditions to prevent degradation. Ultimately, the efficient procurement and transportation of D-erythro-Eritadenine are crucial steps in making this compound available for research and potential commercial use.
⚠️ Safety Considerations
Safety considerations for D-erythro-Eritadenine involve proper handling and storage to prevent accidental exposure. This compound may cause irritation to the skin, eyes, and respiratory system, so it is important to use personal protective equipment such as gloves, goggles, and a mask when working with it. In case of ingestion or inhalation, seek medical attention immediately.
Hazard statements for D-erythro-Eritadenine include “Causes skin irritation,” “Causes serious eye irritation,” and “May cause respiratory irritation.” These statements indicate the potential risks associated with exposure to this compound and emphasize the importance of taking precautions to avoid contact with the skin, eyes, and respiratory system.
Precautionary statements for D-erythro-Eritadenine include “Wash hands and exposed skin thoroughly after handling,” “Wear protective gloves/eye protection/face protection,” and “If inhaled, remove person to fresh air and keep comfortable for breathing.” These statements provide guidelines for handling this compound safely and minimizing the risk of adverse health effects. It is important to follow these precautions when working with D-erythro-Eritadenine to ensure the well-being of laboratory personnel.
🔬 Potential Research Directions
Research on D-erythro-Eritadenine could potentially focus on its effects on cholesterol metabolism and cardiovascular health. Investigating its mechanism of action in reducing cholesterol levels and its potential as a therapeutic agent for hypercholesterolemia could be a promising avenue of study.
Furthermore, exploring the impact of D-erythro-Eritadenine on liver function and lipid metabolism could provide valuable insights into its overall health benefits. Understanding how this compound interacts with enzymes and pathways involved in lipid metabolism could shed light on its potential in preventing liver diseases and metabolic disorders.
Additionally, research could be conducted to elucidate the bioavailability and pharmacokinetics of D-erythro-Eritadenine in the human body. Studying its absorption, distribution, metabolism, and excretion could help optimize dosing regimens and evaluate its efficacy in clinical settings. Investigating its safety profile and potential drug interactions is also crucial for future development as a therapeutic agent.
🧪 Related Compounds
D-threo-Eritadenine is a compound with a similar molecular structure to D-erythro-Eritadenine. This compound also contains a purine scaffold with a substituted adenine moiety. However, the arrangement of substituents on the carbon atoms differ between the two compounds. D-threo-Eritadenine is an isomer of D-erythro-Eritadenine, where the hydroxyl group and the amino group are located on opposite sides of the molecule.
Another similar compound is D-lyxo-Eritadenine, which is an epimer of D-erythro-Eritadenine. In this compound, the hydroxyl and amino groups are oriented in a different configuration compared to D-erythro-Eritadenine. Despite the structural differences, D-lyxo-Eritadenine retains the purine scaffold with the substituted adenine moiety characteristic of D-erythro-Eritadenine. The different arrangement of groups on the chiral carbon atom gives rise to distinct properties and potentially different biological activities.
A related compound to D-erythro-Eritadenine is D-ribo-Eritadenine, which shares the same purine scaffold but with a ribose moiety attached to the adenine ring. The substitution pattern on the adenine moiety remains consistent with D-erythro-Eritadenine. However, the presence of the ribose sugar alters the overall properties and potential interactions with biological targets. D-ribo-Eritadenine may exhibit varying bioactivity compared to D-erythro-Eritadenine due to the differences in molecular structure.
